Neoadjuvant chemotherapy before surgery in cervical cancer

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Trials

Background:

• Neoadjuvant chemotherapy (NAC) is administered before primary treatment for various cancers.
• Intravenous NAC before radical surgery for cervical cancer has been explored in 18 phase II trials.
• Cisplatin-based regimens are common, with generally modest toxicity, except for bleomycin-induced pulmonary effects.

Purpose of the Study:

• To review the efficacy and toxicity of neoadjuvant chemotherapy in cervical cancer patients.
• To evaluate the impact of NAC on surgical operability and survival outcomes.
• To provide recommendations for future neoadjuvant chemotherapy trial designs in cervical cancer.

Main Methods:

• Review of 18 phase II clinical trials evaluating NAC before radical surgery for cervical cancer.
• Analysis of objective response rates, clinical complete response rates, and operability based on International Federation of Obstetrics and Gynecology (FIGO) stage.
• Examination of survival data from historical controls and limited prospective trials.

Main Results:

• High objective response rates (47-88%) and variable clinical complete response rates (7-28%) were observed, decreasing with advanced FIGO stage.
• Operability decreased with increasing stage (58-94%).
• Most trials showed comparable survival to historical controls; only one prospective trial suggested a survival advantage for tumors >60 cm³; NAC before radiation therapy showed no benefit or reduced survival.

Conclusions:

• Neoadjuvant chemotherapy in cervical cancer is feasible with modest toxicity and high response rates, but survival benefits are not consistently demonstrated.
• Current evidence suggests limiting NAC trials to early-stage (FIGO I-II) cervical cancer patients with tumor volume >60 cm³.
• Future research should focus on refining patient selection for NAC to optimize treatment outcomes and avoid potential harm.